FDA's Anticipated Proposed Rulemaking for Direct-to-Consumer Advertising

By Rebecca Zadaka

Following its 2025 direct-to-consumer (DTC) advertising actions, including a Presidential Memorandum and a wave of enforcement, the U.S. Food and Drug Administration (FDA) has initiated proposed rulemaking to close the adequate provision “loophole” for pharmaceutical advertisements. The proposed rulemaking would amend the prescription drug advertising regulations at 21 C.F.R. § 202.1 to eliminate the "brief summary" requirement and instead require DTC ads broadcast through media such as radio and television to disclose all “relevant risk and safety information to consumers within the confines of the ad itself.”

How the Adequate Provision Framework Supports DTC Advertising

For nearly three decades, pharmaceutical ads have been able to meet fair balance standards by combining a major statement of key risks with directions for accessing full prescribing information (e.g., via a website, toll-free number, or print insert). This framework has made modern broadcast DTC advertising commercially feasible by allowing advertisers to direct consumers to additional sources for the full FDA-approved prescribing information without making the advertisements too long. 

How FDA’s Proposed Rule Could Change Broadcast DTC Advertising

The proposed rule indicates that FDA now intends to eliminate that option and require the safety information to be presented within the advertisement itself. Although FDA has not yet published the proposed text of the rule, the potential implications for companies could be substantial. This change could dramatically lengthen advertisements, requiring more airtime and thereby increasing advertisers’ costs and limiting the time available to communicate efficacy information. Ultimately, it could make traditional broadcast advertising economically impractical for many prescription drug manufacturers. The proposed rule could function as a de facto end to broadcast DTC prescription drug advertising if adopted as described.

FDA’s Rationale and the Proposed Rulemaking Timeline

FDA cites several reasons for this change, including its view that the current procedure "has created potential patient confusion and harm from inappropriate demand for medications, distorting the doctor-patient relationship leading to misalignment of therapeutic choices with actual patient needs, and the misallocation of healthcare resources and government overspending." Despite this, the basis for these reasons was not provided.

The publication of a Notice of Proposed Rulemaking is set for December 2026. As with any proposed rule, stakeholders will have an opportunity to submit comments before FDA considers issuing a final regulation. Because this proposal would represent one of the most significant changes to prescription drug advertising regulations in decades, pharmaceutical manufacturers, advertising agencies, and other stakeholders should closely monitor the rulemaking process and evaluate how potential changes could affect existing marketing strategies and promotional review processes.

Although FDA maintains that the proposal would not constitute a ban or impose an unreasonable burden, it does state that it expects the impact on advertising spending “to be economically significant, with annual costs exceeding $100 million for at least one year.” Despite these costs, FDA believes that the rule’s patient-education benefits would outweigh them. 

“If finalized, this rule could fundamentally reshape pharmaceutical television and radio advertising by making traditional DTC broadcast ads significantly more expensive and, for some products, no longer commercially viable.” 

Rebecca Zadaka, Associate Attorney

How Gardner Law Can Help

Gardner Law will continue to monitor developments related to FDA's proposed rule and its potential impact on prescription drug advertising. The proposed rule most directly affects pharmaceutical companies, but medical device companies should also take note of FDA’s increased scrutiny of consumer-directed promotion. Companies engaged in consumer-directed promotion should be prepared to assess whether future advertising campaigns and existing promotional review procedures will need to be modified if FDA ultimately adopts the proposed revisions to the broadcast advertising regulations.